Clinical trials: High-Risk Cancer
Acute Lymphoblastic Leukemia
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
Pharmacogenomics (PG) offers the opportunity to individualize treatment according to patient genetic variations which influence activity of enzyme metabolizing or acting in the pathway of prescribed chemotherapy drugs.
- Trial name
- NCT02670564
- Testing
- Pharmacogenomics, Busulfan plasma level measurements
- Where
- 4 sites in Switzerland
- Volunteers
- 1,000 people
- Sponsor
- Swiss Pediatric Oncology Group
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Bladder Cancer
Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer
Non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence (60 to 70%) and progression (20 to 30%) to muscle-invasive bladder cancer (MIBC).
- Trial name
- IMMUN VESSIE (NCT04726735)
- Testing
- Samples of bladder tissue
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Anal Cancer, Bladder Cancer
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
RATIONALE: Fiber may lessen bowel side effects caused by radiation therapy. It is not yet known whether a high-fiber diet is more effective than a low-fiber diet in preventing bowel side effects caused by radiation therapy.
- Conditions
- Anal Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer
- Trial name
- NCT01170299
- Testing
- dietary intervention, laboratory biomarker analysis, gastrointestinal complications management/prevention
- Where
- United Kingdom
- Volunteers
- 177 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non-Hodgkin's Lymphoma
Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)
The purpose of this trial is to investigate the clinical benefit of the dose intensified regimen, Bi-CHOP in comparison to standard CHOP for advanced intermediate or high grade non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00133302
- Testing
- Standard CHOP, Bi-CHOP (dose intensified CHOP)
- Where
- Japan
- Volunteers
- 450 people
- Sponsor
- Japan Clinical Oncology Group
Glioma, Glioma of Brain
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
This is a 2 strata pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The study will use a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel…
- Conditions
- Glioma, Glioma of Brain, Cancer, Pediatric Cancer
- Trial name
- PNOC008 (NCT03739372)
- Testing
- Specialized tumor board recommendation
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Osteosarcoma, Spindle Cell Sarcoma of Bone
Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
Methotrexate is one of the most effective chemotherapy drugs in the treatment of osteosarcoma and some other types of bone sarcoma which are treated the same way as osteosarcoma.
- Trial name
- NCT02022358
- Testing
- Glucarpidase, Methotrexate, Folinic Acid
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- University College, London
Cancer of Cervix
Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study
Objective: To evaluate the effectiveness of a combined strategy of human papillomavirus virus (HPV) vaccination and high-risk HPV screening to reduce the occurrence of neoplasms in the anogenital region and oral cavity among men…
- Trial name
- CONDESA (NCT05149248)
- Testing
- Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine], Two dose, Control group
- Where
- Mexico
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
This phase I/II trial studies the side effects and best dose of donor natural killer cells when given together with donor stem cell transplant and to see how well they work in treating patients with myeloid malignancies that are…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT01823198
- Testing
- Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01839916
- Testing
- therapeutic allogeneic lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Chicago
Neuroblastoma
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- NCT00659984
- Testing
- UltratraceTM Iobenguane I 131 Imaging, UltratraceTM Iobenguane I 131 Therapy
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive…
- Trial name
- NETTER-3 (NCT06784752)
- Testing
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Where
- 67 sites in United States, Canada and 10 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107458
- Testing
- valproic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Leukemia
Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation
Pilot, multicentric, open-label, single-arm, phase I-II clinical trial to evaluate the safety and efficacy of a novel Umbilical Cord Blood Transplantation (UCBT) platform, that consists of a UCBT of the 80 fraction, followed by a…
- Trial name
- NCT02328885
- Testing
- DLI of the 20 fraction of the UCBT
- Where
- 5 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Banc de Sang i Teixits
Neuroblastoma
Chemotherapy in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs.
- Trial name
- NCT00002730
- Testing
- buthionine sulfoximine, melphalan
- Where
- 4 sites in United States
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Recurrence, Metastasis
Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma)
This clinical trial is designed to evaluate the role of lymph node dissection in the prevention of recurrence and metastasis after radical nephroureterectomy for high-risk primary upper tract urothelial carcinoma (UTUC) patients.
- Conditions
- Recurrence, Metastasis, Upper Tract Urothelial Carcinoma, Lymph Node Dissection
- Trial name
- UTUC (NCT03230201)
- Testing
- Lymph node dissection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University First Hospital
Childhood Glioblastoma
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
This phase I/II trials evaluates the feasibility, safety and efficacy of an individualized cancer vaccine, based on autologous, tumor-lysate loaded dendritic cells in children and adolescents with relapsed high-grade gliomas.
- Trial name
- NCT03879512
- Testing
- depletion of regulatory T cells, reoperation, cancer vaccine
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Wuerzburg University Hospital
Brain Tumors
Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors
The investigators plan to improve event free survival rate and reduce treatment related toxicities of pediatric patients with high risk/recurrent CNS tumors by administrating tandem high dose chemotherapy and autologous stem cell…
- Trial name
- NCT01342237
- Testing
- HDCT 1(TTC), HDCT2(MEC)
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Seoul National University Hospital
Lymphoma, HIV
Autologous Transplant in HIV Patients (BMT CTN 0803)
This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients…
- Trial name
- NCT01141712
- Testing
- Autologous transplant, BCNU, Etoposide
- Where
- 16 sites in United States
- Volunteers
- 43 people
- Sponsor
- Medical College of Wisconsin